Meiji Seika Pharma Announces Positive Results in Phase II Study of ME3183, a Novel Highly-Potent Selective PDE4 Inhibitor, in Patients With Moderate-to-Severe Plaque Psoriasis in the United States and Canada
9.8.2023 09:00:00 EEST | Business Wire | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Daikichiro Kobayashi) today announced that ME3183, a novel highly-potent selective phosphodiesterase-4 (PDE4) inhibitor, met the primary endpoint based on “PASI-75”, defined as the proportion of subjects achieving 75% improvement in Psoriasis Area Severity Index (PASI), in phase II clinical trial in patients with moderate-to-severe plaque psoriasis conducted in the United States and Canada.
The phase II clinical trial (NCT05268016)* was conducted to evaluate the efficacy, safety and tolerability of ME3183 after administered once or twice daily for 16 weeks in patients with moderate-to-severe plaque psoriasis. One-hundred and thirty-two patients were enrolled in the United States and Canada. The primary endpoint was defined as the proportion of subjects achieving 75% improvement (“PASI-75”) in Psoriasis Area Severity Index (PASI) Score at Week 16 from baseline. As a result, significantly greater proportion of PASI-75 achievement were observed in ME3183 treatment groups compared to the placebo group, which met the primary endpoint. In addition, early PASI improvement after administration was observed in ME3183 groups. ME3183 was shown to be safe and well tolerated. Details of the study will be presented at an upcoming medical meeting.
ME3183 is an orally-available and selective PDE4 inhibitor discovered by Meiji Seika Pharma. In non-clinical studies, it showed greater anti-inflammatory effect and approximately 30-fold greater inhibitory effect on TNF-α production than the existing orally-available PDE4 inhibitor for psoriasis. At the same time, the distribution of ME3183 in the brain was sufficiently low.
Meiji strives to provide efficacious and safe treatment for unmet medical needs, such as psoriasis and other autoimmune diseases.
*: Meiji Pharma USA Inc. (Teaneck, NJ, President: Yasushi Miyazawa), a wholly owned subsidiary of Meiji, is in charge of the Phase II clinical trial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230808681726/en/
Contact information
Meiji Pharma USA Inc.
Yasushi Miyazawa
President
Telephone: 201-777-7133
E-mail: mpu.contact@meiji-us.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New TOURISE Report Reveals How Traveler Expectations Are Changing the Rules for Global Tourism18.11.2026 14:00:00 EET | Press release
Changing traveler priorities are reshaping global tourism, influencing where people go, how they spend and what they value most from their journeys. A new report released by TOURISE, The Future Traveller, explores these shifts and what they mean for the industry through 2030. Developed in collaboration with Euromonitor International, the report draws on consumer surveys and perspectives from industry leaders. The report finds that travel decisions are increasingly shaped by the priorities and circumstances of each trip, rather than demographics alone. It calls on destinations and businesses to rethink how they attract visitors and measure success, shifting the focus from high-spending travelers to high-value trips that deliver meaningful experiences, support local economies and create lasting benefits for communities. “Travelers are not making decisions as fixed demographic segments. They are responding to purpose, pressures and possibilities of each trip,” said His Excellency Ahmed Al
Grand Prix ACF AutoTech 2027: Applications Open for the 10th Edition18.11.2026 14:00:00 EET | Press release
The Automobile Club de France (ACF) and ESSEC Alumni are launching the 10th edition of the Grand Prix ACF AutoTech, the leading competition for automotive and mobility startups. French and international startups can apply until November 27, 2026 at 11:59 p.m. (CET) at www.grandprixacfautotech.com. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118772168/en/ Jury members and former finalist startups for the launch of 10th Edition of Grand Prix ACF AutoTech (c) Quentin Vaquez Since 2018, the competition has selected 52 finalists, including Chargemap, Hiflow, ChargeGuru and Geolith, who have together raised more than €700 million. Only 6 have failed: a survival rate of nearly 90%. The 2026 edition rewarded Altrove (Grand Prix ACF), Bloomineral (ACF Pioneer Prize and GreenTech Mention) and IoT.bzh (Industrialization Prize). “Ten editions is an achievement we are proud of. The number of applications, rising every year, shows h
Rockwell Automation Signs Definitive Agreement to Acquire AGILOX18.11.2026 14:00:00 EET | Press release
Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced it has signed a definitive agreement to acquire Austria-based AGILOX, a maker of high-end autonomous mobile robots (AMRs) that are driven by self-developed artificial intelligence and swarm networking technology. Together, AGILOX’s proven forklift AMR portfolio and OTTO by Rockwell Automation’s flatbed AMR platform will create a comprehensive autonomous material movement offering, elevating AGILOX from a best-in-class point solution to a cornerstone of a world-class comprehensive production logistics capability. The acquisition will combine OTTO's strong presence in North America with AGILOX's established footprint across Europe. AGILOX will gain access to Rockwell's deep customer relationships in strategic verticals like consumer packaged goods and life sciences. The acquisition will create a stronger partner ecosystem and more than double R
Ant International Pioneers PayNow Deep-Linking for E-Commerce, Explores Government Services Use Case Under MAS’ PayNow Gen2 Initiative18.11.2026 13:40:00 EET | Press release
Ant International is the first partner under the Monetary Authority of Singapore (MAS)’s PayNow Generation 2.0 launch to introduce live use cases for deep-linking for e-commerce and digital government services. The launch is enabled by Antom, its global merchant payment and digitisation services provider, and Antom’s Southeast Asia subsidiary, 2C2P by Antom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118384895/en/ At the Singapore Fintech Festival 2026, MAS announced phase 2 of the PayNow Gen2 report, a joint study by the Association of Banks in Singapore (ABS) and the MAS to define the next wave of innovation for Singapore's instant payments system. “PayNow Gen2 marks another important step in Singapore’s journey towards a more innovative, connected and future-ready payments ecosystem," said Gary Liu, Chief Executive Officer of Antom and Senior Vice President of Ant International. “At Ant International, we believe th
IFF Opens Its First Forest Lab in Brazil's Atlantic Forest to Advance Fragrance and Beauty Innovation18.11.2026 13:30:00 EET | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — today opened its first Forest Lab at Legado das Águas, Brazil's largest private Atlantic Forest reserve. The lab is the next step in the bioprospecting partnership IFF announced in August 2025 with Reservas Votorantim (rV), the green economy division of Brazilian investment firm Votorantim SA, which manages the reserve. Spanning 31,000 hectares and home to nearly 1,000 plant species, Legado das Águas now hosts biodiversity research, scent discovery, perfumery and beauty innovation in one place, while supporting rV's conservation work. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117495933/en/ A scientist in the new IFF Brazil Forest Lab at Legado das Águas, the country’s largest private Atlantic Forest reserve. “The IFF Brazil Forest Lab brings perfumers, scientists and fragrance and beauty brands directly to the source,” said Ana Paul
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
